Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Gem II VR (Model 7229) single-chamber implantable cardioverter defibrillator is released in the U.S. and internationally following FDA approval July 27 of a premarket approval application supplement, the company reports July 29. The 39 cc, 77 gram device offers full-energy (30 Joules) and high-energy (35 Joules) options for ventricular rate responsive pacing therapy and is 20% smaller than its predecessor, the 48 cc Gem ICD. Competitors include Guidant (39 cc Mini IV single-chamber ICD/pacer), St. Jude (single-chamber, 34 cc Profile MD ICD), and Angeion (47 cc single-chamber Lyra 2020 ICD)

You may also be interested in...



Scottish HTA body OKs Lynparza For Earlier Use In Ovarian Cancer

AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.

Switzerland Provides Gateway Into Mainland Europe For BASF’s Hepacor

With the Swiss launch of its Non-Alcoholic Fatty Liver Disease supplement, BASF is looking to make inroads into continental Europe. 

Orchard’s Gene Therapy Under Fast-Track Review At EMA

A handful of new products are under review at the European Medicines Agency. Orchard Therapeutics' gene therapy application will be fast-tracked; Roche's filing for its new flu treatment will not.
UsernamePublicRestriction

Register

MT012123

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel